

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5096328

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
RAMSAY BEVERIDGE	07/11/2018
JEAN-PHILIPPE LECLERC	07/11/2018
ALEXANDRE LEMIRE	07/11/2018
LIANG ZHAO	07/11/2018
CLAUDIO STURINO	07/11/2018
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	PARAZA PHARMA, INC.
<b>Street Address:</b>	2525 MARIE-CURIE AVENUE
<b>City:</b>	MONTREAL, QUEBEC
<b>State/Country:</b>	CANADA
<b>Postal Code:</b>	H4S2E1
<b>PROPERTY NUMBERS Total: 2</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	15799771
<b>PCT Number:</b>	CN2017103499
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(650)952-9881
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	6504678688
<b>Email:</b>	brady.sushma@gene.com
<b>Correspondent Name:</b>	MARK D. KAFKA
<b>Address Line 1:</b>	1 DNA WAY
<b>Address Line 2:</b>	MS 49
<b>Address Line 4:</b>	SOUTH SAN FRANCISCO, CALIFORNIA 94080
<b>ATTORNEY DOCKET NUMBER:</b>	P33885-US AND P33885-WO-1
<b>NAME OF SUBMITTER:</b>	SUSHMA S. BRADY
<b>SIGNATURE:</b>	/Sushma S. Brady/
<b>DATE SIGNED:</b>	08/14/2018

**Total Attachments: 4**

source=P33885-WO-1 Executed Assignment from Paraza Pharma Inventors to Paraza#page1.tif

source=P33885-WO-1 Executed Assignment from Paraza Pharma Inventors to Paraza#page2.tif

source=P33885-WO-1 Executed Assignment from Paraza Pharma Inventors to Paraza#page3.tif

source=P33885-WO-1 Executed Assignment from Paraza Pharma Inventors to Paraza#page4.tif

**CONFIRMATORY ASSIGNMENT**

*Lederc MC 2018/07/11*

WHEREAS, Ramsay Beveridge, Jean-Philippe Lederc, Alexandre Lemire, Liang Zhao and Claudio Sturino ("ASSIGNORS"), have invented new and useful invention(s) as set forth in the application(s) listed in Exhibit A (including any updated Exhibit A as provided herein), to this Confirmatory Assignment (the "INVENTION"), for which application(s) has been filed as identified on **Exhibit A** (including any updated Exhibit A as provided herein); and

WHEREAS, Paraza Pharma, Inc., a corporation having a place of business at 2525 Marie-Curie Avenue, Montreal, Quebec H4S2E1, Canada ("PARAZA"), is desirous of confirming its ownership interest in and to the INVENTION and in and to the applications and patents to be obtained therefor;



NOW, THEREFORE, be it known by all whom it may concern;

For good and valuable consideration the receipt of which is hereby acknowledged, ASSIGNORS confirm that, by virtue of their employment agreement with PARAZA, prior to, and no later than the earliest filing date of the application(s) listed in Exhibit A (including any updated Exhibit A as provided herein), ASSIGNORS had assigned to PARAZA, any and all of their right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to the INVENTION, and in and to any and all applications filed and patents granted therefor, including any application(s) that claim benefit to any application(s) listed in Exhibit A (including any updated Exhibit A as provided herein) and any priority application(s) from which those application(s) claims benefit; or any continuation, division, renewal, or substitute thereof, and patents granted therefor; or any reissue or re-examination, or subsequent patent thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other jurisdictions, and including the right to claim priority to any of the foregoing.

The ASSIGNORS agree and authorize PARAZA, its successors, assigns and delegates, to update Exhibit A from time-to-time, to include any applications filed by PARAZA, its successors, assigns and delegates in and to the INVENTION when known, including i) any international application (which includes PCT applications) and other applications that claim priority to the application(s) listed in Exhibit A; and ii) any priority applications from which those international or other application(s) claim benefit, which authority includes the right to attach an updated Exhibit A to this Confirmatory Assignment that lists the foregoing applications, without any further action by ASSIGNORS. ASSIGNORS agree and acknowledge that such updated Exhibit A is an Exhibit A under this Confirmatory Assignment.

The terms and covenants of this Confirmatory Assignment shall inure to the benefit of PARAZA, its successors, assigns or delegates, and shall be binding upon the ASSIGNORS, their respective heirs, successors and assigns.


IN WITNESS WHEREOF the ASSIGNORS and PARAZA have executed this Confirmatory Assignment and accepted the terms thereof.



Ramsay Beveridge Date

Mailing address:  
2525 Marie-Curie Avenue  
Montreal, Quebec H4S 2E1  
Canada

Citizenship: Canada



Witness (signature)



Jean-Philippe Leclerc Date

Mailing address:  
2525 Marie-Curie Avenue  
Montreal, Quebec H4S 2E1  
Canada

Citizenship: Canada



Witness (signature)

Alexandre Lemire Date

Mailing address:  
2525 Marie-Curie Avenue  
Montreal, Quebec H4S 2E1  
Canada

Citizenship: Canada



Witness (signature)

Liang Zhao July - 11<sup>th</sup> - 2018  
Date

Mailing address:  
2525 Marie-Curie Avenue  
Montreal, Quebec H4S 2E1  
Canada

Citizenship: Canada

Niane Lawvé  
Witness (signature)

Claudio Sturino July 11<sup>th</sup>, 2018  
Date

Mailing address:  
2525 Marie-Curie Avenue  
Montreal, Quebec H4S 2E1  
Canada

Citizenship: Canada

Niane Lawvé  
Witness (signature)

Paraza Pharma, Inc. July 24, 2018  
Date

Name: ARSHAD SIDDIQUI

Title: PRESIDENT & CEO

**EXHIBIT A TO CONFIRMATORY ASSIGNMENT**

<b>Docket No.</b>	<b>Title</b>	<b>Serial Number</b>	<b>Filing Date</b>
P33885-WO-1	Therapeutic Compounds and Methods of Use Thereof	PCT/CN2017/103499	26 September 2017